BioLineRx Ltd. (BLRX)

$1.87

+0.11 (+6.25%)
Rating:
Recommendation:
Buy
Symbol BLRX
Price $1.87
Beta 1.404
Volume Avg. 0.12M
Market Cap 89.546M
Shares () -
52 Week Range 1.01-3.15
1y Target Est -
DCF Unlevered BLRX DCF ->
DCF Levered BLRX LDCF ->
ROE -49.12% Strong Sell
ROA -35.45% Strong Sell
Operating Margin -
Debt / Equity 19.54% Neutral
P/E -
P/B 1.30 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BLRX news


Philip Serlin
Healthcare
Biotechnology
NASDAQ Capital Market

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.